Figure 4
From: Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
PROSTVAC mediated anti-tumor efficacy and antigen spreading. (A & B) BALB/c mice (10-20/group) were challenged by i.d. injection of RM-11-PSA cells on day 1 and treated 3 times at weekly intervals as described in text. Graphs show data from 2 independently performed experiments. (C) Previously-challenged, tumor-free PROSTVAC V/F-treated mice (n = 6) and naïve BALB/c (n = 10) were injected i.d. with 2E5 RM11-WT cells. ****P < 0.0001.